PMID- 26038676
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150603
LR  - 20240323
IS  - 1476-7961 (Print)
IS  - 1476-7961 (Electronic)
IS  - 1476-7961 (Linking)
VI  - 13
IP  - 1
DP  - 2015
TI  - Serum tryptase detected during acute coronary syndrome is significantly related 
      to the development of major adverse cardiovascular events after 2 years.
PG  - 14
LID - 10.1186/s12948-015-0013-0 [doi]
LID - 14
AB  - BACKGROUND: One of the greatest challenges in cardiovascular medicine is to 
      define the best tools for performing an accurate risk stratification for the 
      recurrence of ischemic events in acute coronary syndrome (ACS) patients. METHODS: 
      We followed 65 ACS patients enrolled in a previous pilot study for 2 years after 
      being discharged, focusing on the occurrence of major adverse cardiovascular 
      events (MACE). The relationship between serum tryptase levels on admission, 
      SYNergy between percutaneous coronary intervention with the TAXUS drug-eluting 
      stent and the cardiac surgery score (SX-score), cardiovascular complexity and 
      MACE at 2 years follow-up were analyzed. RESULTS: The ACS population was divided 
      in two groups: patients with MACE (n = 23) and patients without MACE (n = 42). 
      The tryptase measurement at admission (T0) and at discharge (T3) and SX-score 
      were higher in patients who experienced MACE than in those without (p = 0.0001, 
      p < 0.0001 and p = 0.006, respectively). Conversely, we found no significant 
      association between MACE and C-reactive protein (CRP), and between MACE and 
      maximum level of high-sensitivity troponin (hs-Tn) values. Among all patients 
      with MACE, 96% belonged to the group that presented with cardiovascular 
      complexity at the beginning of ACS index admission (p < 0.0001). The predictive 
      accuracy of serum tryptase for MACE at follow up set at the cut-off point of 
      4.95 ng/ml at T0 and of 5.2 ng/ml at T3. Interestingly, patients with both the 
      above cut-off tryptase values at T0 and at T3 presented a 1320% increase in the 
      odds of developing MACE (p < 0.0001). CONCLUSION: In ACS patients, serum tryptase 
      measured during index admission is significantly correlated to the development of 
      MACE up to 2 years, demonstrating a possible long-term prognostic role of this 
      biomarker.
FAU - Pastorello, Elide Anna
AU  - Pastorello EA
AD  - The Department of Allergology and Immunology, Niguarda Ca' Granda Hospital, 
      Milan, Italy.
FAU - Farioli, Laura
AU  - Farioli L
AD  - The Department of Laboratory Medicine, Niguarda Ca' Granda Hospital, Milan, 
      Italy.
FAU - Losappio, Laura Michelina
AU  - Losappio LM
AD  - The Department of Allergology and Immunology, Niguarda Ca' Granda Hospital, 
      Milan, Italy.
FAU - Morici, Nuccia
AU  - Morici N
AD  - The Department of Cardiology1-Emodinamic, Niguarda Ca' Granda Hospital, Milan, 
      Italy.
FAU - Di Biase, Matteo
AU  - Di Biase M
AD  - The Department of Cardiology, University of Foggia, Foggia, Italy.
FAU - Nichelatti, Michele
AU  - Nichelatti M
AD  - Service of Biostatistics, Niguarda Ca' Granda Hospital, Milan, Italy.
FAU - Schroeder, Jan Walter
AU  - Schroeder JW
AD  - The Department of Allergology and Immunology, Niguarda Ca' Granda Hospital, 
      Milan, Italy.
FAU - Balossi, Luca
AU  - Balossi L
AD  - The Department of Allergology and Immunology, Niguarda Ca' Granda Hospital, 
      Milan, Italy.
FAU - Klugmann, Silvio
AU  - Klugmann S
AD  - The Department of Cardiology1-Emodinamic, Niguarda Ca' Granda Hospital, Milan, 
      Italy.
LA  - eng
PT  - Journal Article
DEP - 20150602
PL  - England
TA  - Clin Mol Allergy
JT  - Clinical and molecular allergy : CMA
JID - 101152195
PMC - PMC4451876
OTO - NOTNLM
OT  - Acute coronary syndrome
OT  - Biomarker
OT  - Major adverse cardiovascular events
OT  - Mast cell
OT  - Tryptase
EDAT- 2015/06/04 06:00
MHDA- 2015/06/04 06:01
PMCR- 2015/06/02
CRDT- 2015/06/04 06:00
PHST- 2015/01/14 00:00 [received]
PHST- 2015/03/11 00:00 [accepted]
PHST- 2015/06/04 06:00 [entrez]
PHST- 2015/06/04 06:00 [pubmed]
PHST- 2015/06/04 06:01 [medline]
PHST- 2015/06/02 00:00 [pmc-release]
AID - 13 [pii]
AID - 10.1186/s12948-015-0013-0 [doi]
PST - epublish
SO  - Clin Mol Allergy. 2015 Jun 2;13(1):14. doi: 10.1186/s12948-015-0013-0. 
      eCollection 2015.